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Background: Activation of peroxisome proliferator-activated receptor (PPAR)α and PPARδ causes an elevation of tissue
carnitine concentrations through induction of genes involved in carnitine uptake [novel organic cation transporter 2,
(OCTN2)], and carnitine biosynthesis [γ-butyrobetaine dioxygenase (BBD), 4-N-trimethyl-aminobutyraldehyde
dehydrogenase (TMABA-DH)]. Recent studies showed that administration of the plasma lipid-lowering drug niacin
causes activation of PPARα and/or PPARδ in tissues of obese Zucker rats, which have a compromised carnitine
status and an impaired fatty acid oxidation capacity. Thus, we hypothesized that niacin administration to obese
Zucker rats is also able to improve the diminished carnitine status of obese Zucker rats through PPAR-mediated
stimulation of genes involved in carnitine uptake and biosynthesis.
Methods: To test this hypothesis, we used plasma, muscle and liver samples from a recent experiment with obese
Zucker rats, which were fed either a niacin-adequate diet (30 mg niacin/kg diet) or a diet with a pharmacological
niacin dose (780 mg niacin/kg diet), and determined concentrations of carnitine in tissues and mRNA and protein
levels of genes critical for carnitine homeostasis (OCTN2, BBD, TMABA-DH). Statistical data analysis of all data was
done by one-way ANOVA, and Fisher’s multiple range test.
Results: Rats of the obese niacin group had higher concentrations of total carnitine in plasma, skeletal muscle and
liver, higher mRNA and protein levels of OCTN2, BBD, and TMABA-DH in the liver and higher mRNA and protein
levels of OCTN2 in skeletal muscle than those of the obese control group (P < 0.05), whereas rats of the obese
control group had lower concentrations of total carnitine in plasma and skeletal muscle than lean rats (P < 0.05).
Conclusion: The results show for the first time that niacin administration stimulates the expression of genes
involved in carnitine uptake and biosynthesis and improves the diminished carnitine status of obese Zucker rats.
We assume that the induction of genes involved in carnitine uptake and biosynthesis by niacin administration is
mediated by PPAR-activation.
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Niacin (nicotinic acid), a water-soluble vitamin of the
B-complex, is involved in many metabolic pathways as a
precursor of the redox coenzymes nicotinate adenine
dinucleotide (NAD) and NAD phosphate [1]. Besides,
niacin has potent plasma lipid-lowering effects and has
long been used for clinical therapy of dislipidemia, par-
ticularly hypertriglyceridemia, due to the fact that niacin
leads to decreased levels of triglycerides (TAG), very
low-density lipoproteins (VLDL) and LDL in plasma
[1-5]. Even though it has been established that niacin
inhibits lipolysis in adipocytes and thereby reduces the
supply of non-esterified fatty acids (NEFA) for hepatic
TAG synthesis, this effect can only insufficiently explain
the lipid-lowering effect because blood NEFA levels
often rebound during long-term niacin treatment while
the lipid-lowering effect remains [1,6].
With regard to other effects of niacin, which may con-
tribute to its lipid-lowering efficacy, it is noteworthy that
acute administration of niacin causes an increase of the
mRNA levels of peroxisome proliferator-activated re-
ceptor (PPAR)α, PPARδ and the PPAR co-activator
PGC-1α in tissues of male healthy subjects [7]. PPARα
and PPARδ are ligand-dependent transcription factors
which act as important metabolic regulators, especially
in fatty acid catabolism, and are therefore abundantly
expressed in tissues with high rates of fatty acid oxida-
tion such as liver and skeletal muscle [8]. Endogenous
ligand-activation is mediated by NEFA and, physiolo-
gically occurs during fasting when NEFA are released
from adipose tissue und taken up into liver, muscle and
other tissues [9,10]. Transcriptional regulation of genes
by PPARs is mediated by binding of activated PPAR/
retinoid X receptor heterodimers to specific DNA se-
quences, called peroxisome proliferator response ele-
ments, present in and around the promoter of target
genes [8,11,12]. Typical PPARα and PPARδ target genes
are involved in all aspects of fatty acid catabolism, such
as fatty acid uptake, intracellular fatty acid transport,
mitochondrial fatty acid import, and peroxisomal and
mitochondrial fatty acid oxidation [8,13]. In addition to
its function in fatty acid catabolism, it has been recently
established that PPARα and PPARδ are transcriptional
regulators of genes involved in carnitine uptake, like
novel organic cation transporter 2 (OCTN2, encoded by
SLC22A5) [12,14], and/or carnitine biosynthesis, such as
γ-butyrobetaine dioxygenase (BBD, encoded by BBOX1)
and 4-N-trimethyl-aminobutyraldehyde dehydrogenase
(TMABA-DH, encoded by ALDH9) [15,16]. This ex-
plains why physiological or pharmacological PPARα and
PPARδ activation causes an elevation of carnitine con-
centrations in tissues because both, carnitine uptake and
biosynthesis is stimulated [14,17,18]. Transcriptional
regulation of genes involved in carnitine homeostasis byPPARα and PPARδ is in line with their fundamental role
for fatty acid catabolism because oxidation of fatty acids
requires their import into the mitochondrial matrix,
which is dependent on carnitine.
Interestingly, we have recently observed that administra-
tion of a pharmacological dose of niacin to obese Zucker
rats causes elevated mRNA levels of a large set of PPARα
and PPARδ target genes involved in fatty acid catabolism
in skeletal muscle, and markedly lowers plasma lipid levels
[19]. This indicates that niacin administration causes acti-
vation of PPARα and/or PPARδ in tissues of obese Zucker
rats and that the niacin-induced improvement of fatty acid
oxidation capacity of skeletal muscle contributes to the
lipid-lowering effect of niacin. Since PPARα and PPARδ
activation stimulates carnitine uptake and biosynthesis, it
is likely that niacin enhances tissue carnitine concen-
trations, which also contributes to the improvement of
mitochondrial fatty acid utilization. In light of this, we
hypothesized that niacin administration causes a sti-
mulation of the expression of genes involved in carnitine
uptake and biosynthesis and thereby increases tissue
carnitine concentrations. Considering that genetic or diet-
induced obesity in rodents was found to result in a com-
promised carnitine status due to a reduced capacity of the
body to synthesize and take up carnitine [20-22], it may
be expected that such an effect of niacin is particularly
useful in obesity. To test our hypothesis, we therefore
used plasma, muscle and liver samples from a recent ex-
periment with obese Zucker rats, an established genetic
model of human obesity, and determined concentrations
of carnitine and mRNA and protein levels of genes critical
for carnitine homeostasis in liver and skeletal muscle [19].
Methods
Animals and diet
The obese (fa/fa) Zucker rat (Crl:ZUC-Leprfa; Charles
River, France) was used as animal model, which is a widely
used genetic model of obesity, metabolic syndrome and
diabetes. For this study, we used plasma, muscle and liver
samples from an animal experiment performed recently
by our group [19], in which twelve, 8- to 10-wk old male
obese Zucker rats were randomly divided into two groups
of each 10 rats. In addition, 10 male heterozygote lean
(fa/+) Zucker rats were used. The rats received two dif-
ferent semi-purified diets which were composed according
to the recommendations of the American Institute of
Nutrition (AIN)-93G [23]. The first diet containing 30 mg
supplemented niacin per kg diet, which was sufficient to
cover the niacin requirement, was fed to the lean group
and the obese control group, whereas the second diet
containing 780 mg supplemented niacin (Lonza, Basel,
Switzerland) per kg diet was fed to the obese niacin group.
The lean group served as a “healthy” reference group in
order to demonstrate the effect of the obese phenotype on
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cluded in this experiment, because niacin at pharma-
cological doses does not exert a lipid-lowering action in
healthy subjects with normal blood lipid levels and was
not expected to cause an alteration of carnitine homeosta-
sis. The diets were fed ad libitum and water was available
ad libitum for a period of 28 days. Further details regar-
ding diet composition, animal keeping and sample collec-
tion are shown in our previous publication [19]. In
Accordance with Article 4 par. 3 of the German Animal
Welfare Law all animals were humanely killed for scien-
tific purpose approved by the Animal Welfare Officer of
the Justus-Liebig-University, JLU No. 450_AZ.
Determination of plasma concentrations of nicotinic acid,
nicotinamide (NAM), and nicotinuric acid (NUA)
The concentrations of nicotinic acid, NAM and NUA in
plasma were determined by LC-MS/MS according to the
method from Liu et al. [24] with slight modifications
which have been reported recently [25].
Determination of concentrations of total carnitine and
carnitine precursors in plasma, muscle and liver
Tandem mass spectrometry was used for determining
the concentrations of free carnitine, acetyl-carnitine, and
carnitine precursors [6-N-trimethyllysine (TML), butyro-
betaine (BB)] in plasma, M. gastrocnemius and liver ac-
cording the method of Hirche et al. [26]. Total carnitine
was calculated as the sum of free carnitine and acetyl-
carnitine. Deuterated carnitine-d3 (Cambridge Isotype
Laboratories, Andover, MA, USA) was used as internal
standard.
RNA isolation and qPCR (quantitative realtime RT-PCR)
analysis
Total RNA was isolated from 20 mg skeletal muscle and
liver tissue using Trizol™ reagent (Invitrogen, Karlsruhe,
Germany) according to the manufacturer’s protocol. RNA
isolation, cDNA synthesis and qPCR were performed as
recently described [27]. The three most stable out of six
tested potential reference genes were CANX, TOP1,
YWHAZ in liver and RPL13, TOP1, YWHAZ in M. gastro-
cnemius. Data on qPCR performance for each gene mea-
sured in liver are shown in Table 1.
Western blotting
Homogenates were prepared from frozen tissue aliquots
using RIPA buffer (50 mM Tris, 150 mM NaCl, 10% gly-
cerol, 0.1% SDS, 1% Trition X-100, 1 mM EDTA, 0.5%
deoxycholate, 1% protease inhibitor mix; pH 7.5). Using the
bicinchoninic acid protein assay kit (Interchim, Mantluçon,
France) the protein concentrations in the homogenates
were determined with BSA as standard. 30 μg protein of
each homogenate was separated on 12.5% SDS-PAGE andfinally electrotransferred to a nitrocellulosemembrane (Pall,
Pensacola, USA). To verify the loading of equal amounts of
protein Ponceau S (Carl Roth, Karlsruhe, Germany) stai-
ning was used. After incubation of the membranes with
blocking solution for 1 hour, the membranes were incu-
bated with the primary antibodies against OCTN2 (poly-
clonal Anti-Solute carrier family 22 member 5 antibody;
Abcam, Cambridge, UK), BBD (monoclonal anti-BBOX1
antibody; Abcam, Cambridge, UK), TMABA-DH (poly-
clonal anti-TMABA-DH antibody, Abnova, Taipei, Taiwan),
and glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
(monoclonal anti-GAPDH antibody, Abcam, Cambridge,
UK) as a reference protein. The membranes were washed,
and then incubated with a horseradish peroxidase-
conjugated secondary monoclonal anti-mouse-IgG anti-
body (Sigma-Aldrich, Steinheim, Germany) for BBD and
GAPDH and polyclonal anti-rabbit-IgG antibody (Sigma-
Aldrich, Steinheim, Germany) for OCTN2 and TMABA-
DH. Afterwards, blots were developed using ECL Select
(GE Healthcare, München, Germany). The signal in-
tensities of the specific bands were detected with a Bio-
Imaging system (Syngene Cambridge, UK) and quantified
using Syngene GeneTools software (nonlinear dynamics).
Statistics
Statistical analysis of all data was done by one-way
ANOVA using the Minitab Statistical Software (Rel.
13.0, State College, PA, USA). Means of the three groups
were compared by Fisher’s multiple range test. Means
were considered significantly different for P < 0.05. Data
presented are shown as means ± SEM.
Results
Body weights, feed intake and feed conversion ratio
Initial and final body weights were higher in the obese nia-
cin group (362 ± 10 g; 506 ± 14 g; n = 10) and the obese
control group (356 ± 6 g; 501 ± 8 g; n = 10) than in the lean
group (270 ± 3 g; 366 ± 5 g; n = 10) (P < 0.05). Daily body
weight gains and daily feed intake were higher in the obese
niacin group (5.09 ± 0.22 g; 26.6 ± 0.7 g/d; n = 10) and the
obese control group (5.12 ± 0.14 g; 25.4 ± 0.6 g/d; n = 10)
than in the lean group (3.35 ± 0.10 g; 19.7 ± 0.3 g/d; n = 10)
(P < 0.05). Feed conversion ratio was higher in the lean
group (5.92 ± 0.13 g feed/g body weight gain; n = 10) than
in the obese niacin group (5.27 ± 0.14 g feed/g body weight
gain; n = 10) and the obese control group (4.98 ± 0.09 g
feed/g body weight gain; n = 10) (P < 0.05). The obese nia-
cin group and the obese control group did not differ with
regard to these parameters.
Concentration of NA and its metabolites (NAM and NUA)
in plasma
Rats of the obese niacin group had higher plasma NAM
concentrations than those of the obese control group
Table 1 Characteristics and performance data of the primers used for reference gene-stability measure M and qPCR
Gene
symbol
Primer sequence (forward,
reverse; from 5’ to 3’)
NCBI
GeneBank
Product
size (bp)
Skeletal muscle Liver
Slope R2# Efficiency* Slope R2# Efficiency*
ACADL AAGGATTTATTAAGGGCAAGAAGC NM_012819.1 380 bp −4.45 1.000 1.68 −3.54 0.999 1.92
GGAAGCGGAGGCGGAGTC
ACADM CAAGAGAGCCTGGGAACTTG NM_016986.2 154 bp −3.29 0.998 2.01 −3.29 0.998 2.01
CCCCAAAGAATTTGCTTCAA
ACADS ACATCTCTTCCCCACATCGC NM_022512.2 204 bp −2.98 0.999 2.16 −3.55 0.999 1.91
CCGAACTTCAGGATGGGTCC
ACOX1 CTGGGCTGAAGGCTTTTACT NM_017340.2 172 bp −3.60 0.997 1.90 −3.97 0.999 1.79
GCTGTCTGCAGCATCATAAC
ALDH9 TTGAGCGGCTGCGACACGAC NM_022273.2 82 bp - −3.42 0.999 1.96
TGACCTCGCTCCTCCGCGTA
ATP5B GCACCGTCAGAACTATTGCT NM_134364 203 bp −3.58 0.998 1.90 −3.33 0.999 2.00
GAATTCAGGAGCCTCAGCAT
BBOX1 GGATGGGGCTCGCTTGATGCA NM_022629.1 281 bp - −3.38 0.997 1.98
GGAGTCCTGCTCTGGCCTCCT
CANX CCAGATGCAGATCTGAAGAC NM_172008 175 bp −3.30 1.000 2.01 −3.45 0.999 1.95
CTGGGTCCTCAATTTCACGT
MDH1 CAGACAAAGAAGAGGTTGCC NM_033235.1 206 bp −3.41 0.999 1.96 −3.27 0.999 2.02
CGTCAGGCAGTTTGTATTGG
RPL13 CTTAAATTGGCCACGCAGCT XR_086310 198 bp −3.20 0.999 2.05 −3.53 0.997 1.92
CTTCTCAACGTCTTGCTCTG
SLC22A5 GAACTCACGAGCCTCGCACGC NM_019269.1 117 bp −2.98 1.000 2.16 −3.51 1.000 1.93
TCGTCGTAGTCCCGCATGCC
TOP1 GAAGAACGCTATCCAGAAGG NM_022615 137 bp −3.45 0.999 1.95 −3.34 0.998 1.99
GCTTTGGGACTCAGCTTCAT
YWHAZ GACGGAAGGTGCTGAGAAA NM_013011 198 bp −3.11 0.999 2.10 −3.30 0.999 2.01
GCAGCAACCTCAGCCAAGT
#Coefficient of determination of the standard curve. *The efficiency was determined by [10-slope].
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n = 10; P < 0.05). The plasma NAM concentration did not
differ between the obese control group and the lean
group. Plasma concentrations of NA and NUA were
below the limit of detection (0.01 μg/ml) in all groups.
Concentration of carnitine and its precursors in plasma,
gastrocnemius muscle and liver
The concentration of total carnitine in plasma and muscle
was higher in the lean group than in the two obese groups,
but it was higher in the obese niacin group than in the
obese control group (P < 0.05; Table 2). Concentration of
total carnitine in the liver was also higher in the obese nia-
cin group than in the obese control group (P < 0.05;
Table 2), whereas it did not differ between the lean group
and the obese control group.Concentrations of the carnitine precursor BB in plasma,
muscle and liver were higher in the lean group than in the
obese control group and the obese niacin group (P < 0.05;
Table 2), but did not differ between the two obese groups.
The concentration of the carnitine precursor TML in
plasma was higher in the lean group than in the two obese
groups (P < 0.05; Table 2), whereas it was not different bet-
ween these groups in liver and skeletal muscle.
Relative mRNA concentrations of PPAR target genes
involved in lipid metabolism of liver and gastrocnemius
muscle
To investigate whether niacin causes an activation of
PPARα and/or PPARδ in muscle and liver, we determined
the mRNA concentrations of classical PPAR target genes
involved in fatty acid oxidation in these tissues. Relative
Table 2 Concentrations of total carnitine and its precursors
(BB and TML) in plasma, liver and gastrocnemius muscle of
lean rats (Lean), obese Zucker rats fed a control diet (Obese
Control) or obese Zucker rats fed a diet supplemented with
780 mg niacin/kg diet (Obese Niacin) for 4 wk1
Lean Obese control Obese niacin
Plasma (μmol/l)
Total Carnitine 62.4 ± 2.1a 39.5 ± 1.1c 48.4 ± 2.9b
γ-Butyrobetaine (BB) 0.75 ± 0.04a 0.36 ± 0.04b 0.42 ± 0.05b
Trimethyllysine (TML) 0.89 ± 0.03a 0.64 ± 0.02b 0.67 ± 0.03b
Skeletal muscle (nmol/g)
Total Carnitine 730 ± 26a 602 ± 28b 681 ± 28a
γ-Butyrobetaine (BB) 10.9 ± 0.5a 8.42 ± 0.40ab 7.31 ± 0.65b
Trimethyllysine (TML) 73.7 ± 11.5 58.7 ± 10.5 58.8 ± 3.8
Liver (nmol/g)
Total Carnitine 289 ± 10b 298 ± 7b 334 ± 12a
γ-Butyrobetaine (BB) 3.32 ± 0.35a 2.12 ± 0.13b 1.93 ± 0.17b
Trimethyllysine (TML) 16.5 ± 1.6 13.5 ± 0.7 14.1 ± 0.8
1Data are expressed as means ± SEM. n = 10 rats/group. a,bValues with different
superscript letters differ, P < 0.05.
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short-chain acyl-CoA-dehydrogenase (ACADS), medium-
chain acyl-CoA-dehydrogenase (ACADM) and long-chain
acyl-CoA-dehydrogenase (ACADL), which are involved in
peroxisomal and/or mitochondrial β-oxidation, in liver
and skeletal muscle were higher in the obese niacin groupTable 3 Relative mRNA concentrations of PPARα and PPARδ tar
LCAD) and genes involved in carnitine uptake (OCTN2) and bios
muscle of lean rats (Lean), obese Zucker rats fed a control diet (O
with 780 mg niacin/kg diet (Obese Niacin) for 4 wk1
Lean
Relative mRN
Skeletal muscle
ACOX1 1.49 ± 0.29ab
SCAD 1.68 ± 0.46ab
MCAD 1.40 ± 0.30ab
LCAD 1.43 ± 0.46ab
SLC22A5 1.25 ± 0.31ab
Liver
ACOX1 0.92 ± 0.14b
SCAD 0.91 ± 0.09b
MCAD 1.19 ± 0.13b
LCAD 0.99 ± 0.17b
SLC22A5 0.78 ± 0.06b
BBOX1 0.76 ± 0.08b
ALDH9 1.00 ± 0.08b
1Data are expressed as means ± SEM. n = 10 rats/group. a,bValues with different supthan in the obese control group and the lean group
(P < 0.05; Table 3).
Relative mRNA concentrations of genes involved in
carnitine uptake in liver and gastrocnemius muscle and
carnitine synthesis in the liver
To study whether niacin influences the expression of
genes involved in carnitine uptake in liver and muscle
and hepatic carnitine synthesis, we evaluated the mRNA
concentrations of SLC22A5, BBOX1 and ALDH9 in liver
and muscle, respectively. BBOX1 and ALDH9 were con-
sidered only in the liver, because the liver is the major
organ responsible for carnitine biosynthesis. In the liver,
the mRNA concentrations of SLC22A5, BBOX1 and
ALDH9 were higher in the obese niacin group than in
the obese control group and the lean group (P < 0.05;
Table 3), but they were not different between the obese
control group and the lean group. The mRNA concen-
tration of SLC22A5 in gastrocnemius muscle was also
higher in the obese niacin group than in the obese con-
trol group (Table 3), but did not differ between the
obese niacin group and the lean group.
Relative protein concentrations of genes involved in
carnitine uptake in liver and gastrocnemius muscle and
carnitine synthesis in the liver
Relative protein concentrations of OCTN2, BBD, and
TMABA-DH in the liver were lower in the obese control
group than in the obese niacin group and the lean groupget genes involved in β-oxidation (ACOX1, SCAD, MCAD,
ynthesis (BBD, TMABA-DH) in liver and gastrocnemius
bese Control) or obese Zucker rats fed a diet supplemented
Obese control Obese niacin
A concentration (fold of obese control = 1.00)
1.00 ± 0.21b 1.89 ± 0.36a
1.00 ± 0.40b 2.69 ± 0.70a
1.00 ± 0.34b 2.24 ± 0.47a
1.00 ± 0.25b 3.78 ± 1.32a
1.00 ± 0.18b 1.93 ± 0.42a
1.00 ± 0.12b 1.42 ± 0.07a
1.00 ± 0.14b 1.57 ± 0.08a
1.00 ± 0.14b 1.76 ± 0.22a
1.00 ± 0.14b 1.57 ± 0.08a
1.00 ± 0.07b 1.42 ± 0.12a
1.00 ± 0.08b 1.54 ± 0.06a
1.00 ± 0.08b 1.40 ± 0.14a
erscript letters differ, P < 0.05.
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Figure 1 Relative protein levels of OCTN2, BBD and TMABA-DH
in liver of lean rats (Lean), obese Zucker rats fed a control diet
(Obese Control) or obese Zucker rats fed a diet supplemented
with 780 mg niacin/kg diet (Obese Niacin) for 4 wk. (A) Bars
represent means ± SEM, n = 10/group. Means without a common
letter differ, P < 0.05. (B) Representative immunoblots specific to
OCTN2, BBD, TMABA-DH and GAPDH as internal control are shown for
one animal per group; immunoblots for the other animals revealed
similar results.
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the obese niacin group and the lean group. Relative pro-
tein concentration of OCTN2 in muscle was higher in
the obese niacin group than in the obese control group
and the lean group (P < 0.05; Figure 2).
Discussion
In the present study, we tested the hypothesis that niacin
administration to obese Zucker rats is able to improve
the carnitine status of obese Zucker rats through PPAR-
stimulated expression of genes involved in carnitine
uptake and biosynthesis. As expected, administration of
780 mg niacin/kg diet for 4 wk to obese Zucker rats
resulted in an about 2-fold elevation of plasma NAM
levels compared to obese control rats, which received a
physiological niacin dose (30 mg/kg diet) sufficient to
cover their niacin requirement. This elevation of plasma
NAM levels was in the range of that reported in other
studies, in which a similar niacin dose was fed to rats
[25,28]. The finding that nicotinic acid and NUA were
not detectable was also not unexpected, because nico-
tinic acid from the diet is rapidly converted to NAD and
NAM in the intestine and liver, from which NAM is re-
leased into the blood stream [29]. Nicotinic acid and
NUA can be found in the systemic blood at significant
levels only when nicotinic acid is administered either i.v.
or as a fast release preparation, because nicotinic acid is
then activated by combination with coenzyme A (CoA)
to form nicotinyl-CoA, which is then conjugated with
glycine to NUA [30]. A key finding of the present study
was that niacin administration in pharmacological doses
results in enhanced carnitine concentrations in plasma,
skeletal muscle and liver and improves the diminished
carnitine status of obese Zucker rats indicating that nia-
cin increases carnitine uptake into tissues and hepatic
carnitine synthesis. Although it has been proposed that
the carnitine precursors TML and BB are rate-limiting
for carnitine biosynthesis [31], we found no difference in
the concentrations of carnitine precursors between the two
obese groups, despite elevated carnitine concentrations in
plasma and liver in the obese niacin group. However, the
observation from the present study that mRNA and pro-
tein levels of OCTN2, BBD and TMABA-DH were signifi-
cantly increased in the liver and skeletal muscle of the
obese niacin group compared to the obese control
group rather suggests that the rate of carnitine biosyn-
thesis and uptake were elevated through stimulating ex-
pression of genes involved in carnitine homeostasis.
Noteworthy, BB is also a good substrate for OCTN2
[32,33] and the liver has a high capacity to convert BB
into carnitine [34]. Thus, it is likely that the niacin-
induced increase in the expression of OCTN2 in the
liver also contributed to an elevated carnitine biosyn-
thesis rate in the liver.
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Figure 2 Relative protein level of OCTN2 in M. gastrocnemius of
lean rats (Lean), obese Zucker rats fed a control diet (Obese
Control) or obese Zucker rats fed a diet supplemented with
780 mg niacin/kg diet (Obese Niacin) for 4 wk. (A) Bars represent
means ± SEM, n = 10/group. Means without a common letter differ,
P < 0.05. (B) Representative immunoblots specific to OCTN2 and
GAPDH as internal control are shown for one animal per group;
immunoblots for the other animals revealed similar results.
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tion of PPARα and/or PPARδ in tissues of rats [19], and
activation of both of them is known to stimulate car-
nitine uptake and biosynthesis [12,14-18], we studied
whether niacin resulted in the activation of PPARα and
PPARδ in the liver and skeletal muscle of obese Zucker
rats. We observed that several PPARα and PPARδ target
genes, such as ACOX1, ACADS, ACADM, ACADL, en-
coding enzymes of fatty acid β-oxidation were elevated
in both, liver and skeletal muscle, of the obese niacin
group compared to the obese control group indicating
that PPARα and/or PPARδ was indeed activated by nia-
cin administration. Regarding that mRNA and protein
levels of OCTN2, BBD and TMABA-DH, which have
been identified either as direct PPARα target genes or to
be regulated by PPARδ [12,14-16], were increased in the
liver and skeletal muscle of the obese niacin group com-
pared to the obese control group suggests that activation
of PPARα and/or PPARδ is responsible for this effect.
Since the selected genes encoding enzymes of fatty acid
β-oxidation but also other genes involved in fatty acid
β-oxidation are target genes of both, PPARα and PPARδ,
it is not possible to differentiate whether niacin activates
either PPARα or PPARδ or both of them. However, re-
cent observations from whole-genome transcriptional
profiling in PPARα knockout and PPARδ knockout mice
suggested that the key regulator of fatty acid oxidationgenes in the liver is PPARα [35], whereas PPARδ, the
predominant PPAR isoform in skeletal muscle, plays this
role in skeletal muscle. It is therefore possible that the
effect of niacin on OCTN2 expression in skeletal muscle
is mediated by PPARδ activation and that on OCTN2,
BBD and TMABA-DH expression in the liver by PPARα
activation.
The mechanism underlying activation of PPARα and/or
PPARδ by niacin remains to be resolved but it may involve
an elevation of circulating levels of NEFA, which serve as
PPAR ligands. Considering the well-known antilipolytic
effect of niacin, an elevation of plasma NEFA levels seems
paradox. However, the rapid decrease of plasma NEFA
concentrations in response to acute administration of
niacin is followed by a marked rebound of plasma NEFA
levels to even above pre-treatment levels [36,37], which
may be responsible for an increased binding to and activa-
tion of PPARs in tissues. The rebound phenomenon has
been explained by the decreasing antilipolytic effect of the
administrated niacin and the parallel stimulation of lipoly-
sis by lipolytic hormones, like epinephrine and cortico-
sterone, which are found at increased levels in plasma
following niacin administration [7,38]. Nevertheless, based
on the present data it still remains speculative if the effect
of niacin on carnitine homeostasis is mediated by activa-
tion of PPARs. Definitive proof can be provided only by
investigating the effect of niacin in PPARα/PPARδ double-
knockout mice in future studies.
Since there is no evidence in the literature that niacin
supplementation stimulates protein catabolism in skel-
etal muscle, we exclude the possibility that niacin caused
the improvement of carnitine status through an en-
hanced release of the carnitine precursor TML, which is
released upon protein degradation, from skeletal muscle.
In line with this assumption, we found no difference in
the TML concentrations in plasma, liver and skeletal
muscle, the main source of TML, between the obese
control and the obese niacin group.
Conclusion
Our study shows for the first time that niacin administra-
tion is able to improve the diminished carnitine status of
obese Zucker rats, an established genetic model of human
obesity. The herein reported effect of niacin on the carni-
tine status is supposed to be beneficial in obese subjects,
because it is well-known that obesity causes an impair-
ment of carnitine status, which was evident also in the
obese Zucker rats. An impaired carnitine status is ge-
nerally detrimental for the metabolic situation in obese
subjects, which is characterized by a chronic excess of
metabolic substrates, because it contributes not only to
reduced fatty acid oxidation capacity and to mitochondrial
dysfunction but also to insulin resistance [20]. Thus,
normalizing an impaired carnitine status is a key for
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denced from the observation that oral carnitine supple-
mentation overcomes not only mitochondrial dysfunction
but also improves glucose tolerance in different rodent
models of obesity [20]. One important factor being causa-
tive for the impaired carnitine status during obesity is
likely a disturbed PPARα function [21] leading to a de-
creased capacity of the liver to synthesize and take up car-
nitine, because PPARα is a critical transcriptional regulator
of genes involved in carnitine homeostasis [12,15-18]. This
is also evident from the finding that PPARα knockout mice
have markedly decreased levels of carnitine in tissues and
plasma [39]. Thus, activation of PPARα in tissues by niacin
is likely responsible for the increased carnitine concentra-
tion in the liver of obese Zucker rats. In agreement with
this, we have recently demonstrated that regular en-
durance exercise, which also causes activation of PPARs in
tissues due to an elevated release of NEFA from adipose
tissue, is able to restore the reduced carnitine levels in
high-fat diet-induced obese mice to those levels found in
non-obese sedentary mice due to activation of PPARs and
PPAR co-activators in the liver and enhancing the mRNA
and protein levels of genes involved in carnitine uptake
and synthesis [22].
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